BTG buys rival for $242M

The UK's BTG has announced plans to acquire Biocompatibles for £177 million, or about $242 million. With the acquisition, BTG gains access to Biocompatibles' oncology products, which include drug coated beads used to treat liver cancer, according to the Financial Times. BTG plans on investing heavily in Biocompatibles' products and development pipeline, the company said in a statement. Report